SCHEMBL2116996

SCHEMBL2116996

CC1(C)OB(c2ccc(NC(=O)OCc3ccccc3)c(Cl)c2)OC1(C)C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.48
RAB9A P51151 2/20 0.48
MAOB P27338 1/20 0.44
OPRK1 P41145 1/20 0.44
AAK1 Q2M2I8 1/20 0.43
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA9 Q16790 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
MGLL Q99685 2/20 0.41
CASP3 P42574 2/20 0.41
LIPG Q9Y5X9 1/20 0.41
HDAC3 O15379 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC2 Q92769 1/20 0.41
HIF1A Q16665 1/20 0.40
POLB P06746 1/20 0.40
ALDH1A1 P00352 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12772940 0.90 NPC1 (0.51) NPC1RAB9AMAOBSMN1; SMN2MGLL
SCHEMBL5785397 0.86 NPC1 (0.47) NPC1RAB9AMAOBCA1CA2
SCHEMBL31480254 0.83 NPC1 (0.46) NPC1RAB9AMAOBSMN1; SMN2MEN1
SCHEMBL4823829 0.82 POLB (0.54) NPC1RAB9AMAOBCA1CA2
SCHEMBL1530791 0.80 MAPT (0.50) NPC1RAB9AMAOBSMN1; SMN2MGLL
SCHEMBL2635870 0.80 CA1 (0.51) RAB9AAAK1CA1CA2CA9
SCHEMBL15116265 0.79 NPC1 (0.46) NPC1RAB9AMAOBSMN1; SMN2MGLL
SCHEMBL4822133 0.78 AAK1 (0.59) AAK1CA1CA2CA9HIF1A
SCHEMBL19510960 0.78 NPC1 (0.44) NPC1RAB9AMAOBSMN1; SMN2MGLL
SCHEMBL25217470 0.77 L3MBTL1 (0.42) NPC1RAB9ASMN1; SMN2LIPG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2627637-B1 N-PYRIDIN-3-YL OR N-PYRAZIN-2-YL CARBOXAMIDES HOFFMANN LA ROCHE (CH) 2016-06-29 EP disclosed
EP-2627637-A1 N-PYRIDIN-3-YL OR N-PYRAZIN-2-YL CARBOXAMIDES F. Hoffmann-La Roche AG (CH) 2013-08-21 EP disclosed
US-8410107-B2 N-pyridin-3-yl or N-pyrazin-2-yl carboxamides HOFFMANN-LA ROCHE INC. (US) 2013-04-02 US disclosed
US-20120094993-A1 N-PYRIDIN-3-YL OR N-PYRAZIN-2-YL CARBOXAMIDES F. HOFFMANN-LA ROCHE AG (CH) 2012-04-19 US disclosed
WO-2012049190-A1 N-PYRIDIN-3-YL OR N-PYRAZIN-2-YL CARBOXAMIDES F. HOFFMANN-LA ROCHE AG (CH) 2012-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120094993-A1 N-PYRIDIN-3-YL OR N-PYRAZIN-2-YL CARBOXAMIDES APOB, CETP, NPC1L1 NPC1 7/4885RAB9A 3480/4885MAOB 951/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.